Biogen (NASDAQ: BIIB) grants director 1,505 RSUs vesting by 2026

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Rowinsky Eric K reported acquisition or exercise transactions in this Form 4 filing.

Biogen Inc. director Eric K. Rowinsky received an equity grant as part of his compensation. He was awarded 1,505 shares of common stock in the form of restricted stock units at a grant price of $0.00 per share.

After this grant, he directly holds 25,844 shares of Biogen common stock. The restricted stock units vest on the earlier of the next annual meeting or the anniversary of the June 9, 2026 grant date, tying his compensation to the company’s future performance over roughly a one-year period.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Rowinsky Eric K

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	1,505	$0.00	--

Holdings After Transaction: Common Stock — 25,844 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

RSU grant size: 1,505 shares Grant price: $0.00 per share Shares held after grant: 25,844 shares

3 metrics

RSU grant size 1,505 shares Restricted stock unit award on June 9, 2026

Grant price $0.00 per share Restricted stock unit compensation grant

Shares held after grant 25,844 shares Total Biogen common stock directly owned after transaction

Key Terms

restricted stock units, Form 4, beneficial ownership

3 terms

restricted stock units financial

"The restricted stock units vest on the earlier of (i) the next annual meeting"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Form 4 regulatory

"INSIDER FILING DATA (Form 4):"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

beneficial ownership financial

"transactionSummary includes exerciseCount/exerciseShares for derivative exercises"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

06/11/2026 - 05:46 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Rowinsky Eric K

(Last)

(First)

(Middle)

BIOGEN INC.

225 BINNEY STREET

(Street)

CAMBRIDGE

MASSACHUSETTS

02142

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BIOGEN INC. [ BIIB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/09/2026		A		1,505⁽¹⁾	A	$0	25,844	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The restricted stock units vest on the earlier of (i) the next annual meeting or (ii) the anniversary of the date of grant of June 9, 2026.

	/s/ Wendell Taylor, Attorney in Fact for Eric K. Rowinsky	06/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Biogen (BIIB) director Eric K. Rowinsky receive in this Form 4?

Eric K. Rowinsky received a grant of 1,505 restricted stock units of Biogen common stock. This compensation-related award was made at a grant price of $0.00 per share and represents additional equity tied to his service as a company director.

Is Eric K. Rowinsky’s Biogen Form 4 transaction a stock purchase or a grant?

The Biogen Form 4 for Eric K. Rowinsky reports a grant, not an open-market purchase. He acquired 1,505 shares through a restricted stock unit award, a common form of non-cash director compensation, at a stated price of $0.00 per share.

When do Eric K. Rowinsky’s 1,505 Biogen restricted stock units vest?

The 1,505 restricted stock units vest on the earlier of Biogen’s next annual meeting or the anniversary of the June 9, 2026 grant date. This structure typically aligns director incentives with shareholders over approximately one year of board service.

How many Biogen shares does Eric K. Rowinsky hold after this Form 4 grant?

Following the grant, Eric K. Rowinsky directly holds 25,844 shares of Biogen common stock. This total includes the 1,505 shares underlying the newly awarded restricted stock units, as reported in the Form 4’s post-transaction ownership figure.

Does the Biogen (BIIB) Form 4 show any stock sales by Eric K. Rowinsky?

The Form 4 does not report any stock sales by Eric K. Rowinsky. It only shows an acquisition of 1,505 shares through a restricted stock unit grant, with no corresponding dispositions or open-market sale transactions listed in the filing.

What type of security is reported in Eric K. Rowinsky’s Biogen Form 4?

The Form 4 lists Biogen common stock, delivered via restricted stock units. These units convert into common shares upon vesting, subject to the schedule that triggers on the earlier of the next annual meeting or the June 9, 2026 grant anniversary.